This study shows that neoadjuvant treatment with chemotherapy, trastuzumab, and pertuzumab instead of chemotherapy and trastuzumab is of significant benefit in early-stage HER2-positive female breast cancer patients. Here, ERBB2 is linked to breast carcinoma.